Assessing Transplant Eligibility and Fitness for Intensive Chemotherapy

Author(s):

Margaret T. Kasner, MD,Christian Fidler, MD

Panelists discuss how identifying candidates for allogeneic transplant in secondary acute myeloid leukemia involves a comprehensive assessment of disease characteristics, patient factors, and timing considerations, while also evaluating fitness for intensive chemotherapy induction using specific criteria to guide treatment decisions.

EP: 1.Implementing Updates to AML Classification Guidelines

EP: 2.Treatment Goals in Secondary AML

EP: 3.The Role of Molecular and Cytogenetic Testing in Secondary AML

EP: 4.Patient-Centered Decision-Making in Secondary AML Treatment

Now Viewing

EP: 5.Assessing Transplant Eligibility and Fitness for Intensive Chemotherapy

EP: 6.Evidence-Based Approaches to Intensive Chemotherapy in Secondary AML

EP: 7.Navigating Intensive Chemotherapy in the Community Setting

EP: 8.Optimizing AML Care Through Academic-Community Collaboration

EP: 9.Practice Pearls for Treatment of Secondary AML in the Community Setting

Video content above is prompted by the following:

Please describe how you identify individuals eligible for allogeneic transplant.
- Discuss when you begin the process of referring a patient for transplant.
How do you determine if a patient is fit for intensive chemotherapy induction in the frontline setting?
- What are some criteria that you use to determine if patients are eligible for intensive chemotherapy induction?